Publication

Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit

De Vries, G. T., Van Ojik, A. L., Hoogendoorn, M. & Van Roon, E. N., 29-Nov-2019, In : Pharmaceutisch Weekblad. 154, 48, p. 24-30 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

De Vries, G. T., Van Ojik, A. L., Hoogendoorn, M., & Van Roon, E. N. (2019). Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit. Pharmaceutisch Weekblad, 154(48), 24-30.

Author

De Vries, G.T. ; Van Ojik, A.L. ; Hoogendoorn, M. ; Van Roon, E.N. / Therapeutic use of low molecutar weight heparins in obese patients : Dosing based on body weight without cut-off timit. In: Pharmaceutisch Weekblad. 2019 ; Vol. 154, No. 48. pp. 24-30.

Harvard

De Vries, GT, Van Ojik, AL, Hoogendoorn, M & Van Roon, EN 2019, 'Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit', Pharmaceutisch Weekblad, vol. 154, no. 48, pp. 24-30.

Standard

Therapeutic use of low molecutar weight heparins in obese patients : Dosing based on body weight without cut-off timit. / De Vries, G.T.; Van Ojik, A.L.; Hoogendoorn, M.; Van Roon, E.N.

In: Pharmaceutisch Weekblad, Vol. 154, No. 48, 29.11.2019, p. 24-30.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

De Vries GT, Van Ojik AL, Hoogendoorn M, Van Roon EN. Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit. Pharmaceutisch Weekblad. 2019 Nov 29;154(48):24-30.


BibTeX

@article{da7587e4c836468ab4ea5362fa12431b,
title = "Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit",
abstract = "The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended.",
keywords = "adult, article, body weight, drug overdose, human, molecular weight, morbid obesity, obese patient, pharmacokinetics, therapeutic dose",
author = "{De Vries}, G.T. and {Van Ojik}, A.L. and M. Hoogendoorn and {Van Roon}, E.N.",
year = "2019",
month = nov,
day = "29",
language = "Dutch",
volume = "154",
pages = "24--30",
journal = "Pharmaceutisch Weekblad",
issn = "0031-6911",
publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",
number = "48",

}

RIS

TY - JOUR

T1 - Therapeutic use of low molecutar weight heparins in obese patients

T2 - Dosing based on body weight without cut-off timit

AU - De Vries, G.T.

AU - Van Ojik, A.L.

AU - Hoogendoorn, M.

AU - Van Roon, E.N.

PY - 2019/11/29

Y1 - 2019/11/29

N2 - The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended.

AB - The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended.

KW - adult

KW - article

KW - body weight

KW - drug overdose

KW - human

KW - molecular weight

KW - morbid obesity

KW - obese patient

KW - pharmacokinetics

KW - therapeutic dose

M3 - Article

VL - 154

SP - 24

EP - 30

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

SN - 0031-6911

IS - 48

ER -

ID: 110383311